Wilms Tumor 1 (WT-1) is a gene that is involved in the normal development of the kidneys and other organs. However, when the WT-1 gene becomes abnormal, it can make proteins involved in the development of some cancers, including leukemia.
The purpose of this study is to evaluate the safety and effectiveness of a vaccine against the WT-1 protein which is designed to cause an immune response against acute myeloid leukemia (AML). The WT-1 vaccine is made up of protein pieces that the immune system can recognize as abnormal.
The vaccine will be evaluated in patients with AML that is in remission. Researchers want to determine if the WT-1 vaccine can eliminate any residual AML cells remaining in the body and prevent a recurrence of the disease.